Poolbeg Pharma: Positive Results from POLB 001 LPS Human Challenge Trial
Strong potential for POLB 001 to be a blockbuster treatment for severe influenza
Key Highlights
· POLB 001 resulted in a highly significant reduction in p38 MAP kinase driven cytokines
· POLB 001 treatment exhibited a marked reduction in multiple markers of systemic and local inflammation compared with placebo
· Trial results demonstrate expected utility in severe influenza and other acute inflammatory conditions
